We’re getting ready to wrap up #AACR26 today, but not before once again congratulating @danafarber.bsky.social’s Eliezer Van Allen, MD, and Kimberly Stegmaier, MD, recipients of @theaacr.bsky.social 2026 Scientific Achievement Awards. ➡️bit.ly/4mpIN1Q

Today at #AACR26: Noah Fields, MS, in the lab of @danafarber.bsky.social’s Dr. Eliezer Van Allen, presents findings from a familial cancer study suggesting that high-resolution germline genetic testing could benefit patients with familial cancer. ➡️ bit.ly/4crIeQl#AACR26

In a Phase II Clinical Trials poster session, @danafarber.bsky.social’s Dr. Catherine Marinac shares results from a clinical trial in MGUS and smoldering myeloma suggesting short-term metformin may lead to modest improvements in M-protein levels. More research is needed. #AACR26 ➡️ bit.ly/48088JN#AACR26

Today at #AACR26: @danafarber.bsky.social’s Kristen Brantley, PhD, presents study findings highlighting the importance of recommending endocrine therapy for patients facing hormone-receptor positive breast cancer, and of improving treatment adherence by increasing tolerability. ➡️ bit.ly/3OIEe6j#AACR26

New research at #AACR26: @danafarber.bsky.social’s @abdohlman.bsky.social shares results from the largest pan-cancer microbiome analysis to date using metagenomic sequencing. This work unlocks a map of the tumor-associated microbial environment that can help future studies. ➡️ bit.ly/3Q7TytH

Today at #AACR26 @zeyunlu.bsky.social, a research fellow in @sashagusevposts.bsky.social’s lab at @danafarber.bsky.social, presents findings that LLM-based extraction of unstructured clinical notes can provide scalable and accurate characterization of immune-related side effects. ➡️ bit.ly/4mxMtyF

At the #AACR26 press conference, Dr. Omar Nadeem of @danafarber.bsky.social presents results of the phase 2 CAR-PRISM clinical trial, the first to investigate CAR T-cell therapy in pts with high-risk smoldering multiple myeloma. The study also published today at @natmed.nature.com: bit.ly/3Qpatba

Congratulations to @danafarber.bsky.social's Dr. Toni Choueiri who was elected to the Association of American Physicians in recognition of his contributions in basic or translational biomedical research. Read more: bit.ly/4cQw9pn

At #AACR26: Results from CAR-PRISM Trial. Dr. Omar Nadeem says in a small trial for pts with high-risk smoldering myeloma, "This is the 1st time we've seen universal minimal residual disease negativity with a one-time treatment administration." @danafarber.bsky.social ➡️ bit.ly/4tmxcmW

In today’s Clinical Trials Plenary at #AACR26: @danafarber.bsky.social’s Dr. Elizabeth Lee reports promising results from a phase 1 study exploring toxicity reduction in combination therapy with trastuzumab deruxtecan and olaparib in advanced HER2-expressing malignancies. ➡️ bit.ly/3OvT1B5#AACR26

Dr. Alice Shaw @danafarber.bsky.social will highlight emerging science shaping the future of global cancer research and clinical care in today’s #AACR26 Opening Plenary. Learn more: brnw.ch/21wRXs0

Congratulations to @danafarber.bsky.social’s Dr. Alice Shaw, Dr. Kimberly Stegmaier and Dr. Matthew Vander Heiden who were elected as Fellows of the @theaacr.bsky.social Academy Class of 2026. Read more: bit.ly/4suWu0L

#AACR26 kicks off today and we’re proud to highlight over 50 studies including #myeloma, #pancreaticcancer, #breastcancer, #AI and genetic risk factors presented by @danafarber.bsky.social researchers. bit.ly/4cAoXMU#AACR26

New research from @danafarber.bsky.social Kornelia Polyak, MD, PhD, published in @cp-cancercell.bsky.social reveals key mechanisms by which precancerous ductal carcinoma in situ (DCIS) turns into invasive breast cancer. ➡️ bit.ly/4dNXcmf

We’re on our way to #AACR26! Whether you’ll be in San Diego from April 17-22 or attending virtually, follow @danafarbernews.bsky.social for important research findings by @danafarber.bsky.social faculty across a spectrum of cancers. Complete list of DFCI oral abstracts: bit.ly/4sDdXEu#AACR26

“It's a reason for optimism.” @danafarbernews.bsky.social's Andrew Aguirre, MD, PhD, discusses data released this week on the pancreatic cancer drug daraxonrasib, an oral pill that is a multi-selective RAS inhibitor. Read more here: bit.ly/4tg1l7t

Congratulations to @danafarbernews.bsky.social’s Eli Van Allen, MD, and Kimberly Stegmaier, MD, recipients of @theaacr.bsky.social 2026 Scientific Achievement Awards. ➡️ bit.ly/4mpIN1Q

A new study published in @natchembio.nature.com by Mei Ying Ng, PhD, of @danafarber.bsky.social’s Chouchani Lab identifies a druggable cysteine redox switch controlling macrophage cytokine responses and provides a compendium of redox-regulated sites for therapeutic development. bit.ly/47weEI4

In @natrevbioeng.nature.com, new research by @danafarber.bsky.social’s William Shih, PhD, reveals that DNA origami vaccine nanotechnology, DoriVac, holds potential as a versatile, modular vaccine platform, capable of inducing both humoral and cellular immunities. Read more: bit.ly/4dS3oJS

New research in @natureportfolio.nature.com by @danafarber.bsky.social's Spiegelman Lab reveals that irisin-driven cell-cell and inter-tissue interactions improve obesity & glucose intolerance and increase energy expenditure, with no reduced food intake and muscle loss in obese mice. bit.ly/4sdGhgf

Alcohol and pancreatic cancer risk for younger adults: @danafarber.bsky.social’s Dr. Leah Biller discusses with @medscape.com findings and limitations of a new study out of South Korea. ➡️ bit.ly/4tosioO

Congrats to @danafarber.bsky.social’s Xin Gu, PhD, recipient of a 2026 Smith Family Award for Excellence in Biomedical Research. Her research aims to understand how cells recycle proteins directly at the DNA and how this recycling machinery might be harnessed to improve human health. bit.ly/4v4eP7h

Artwork created by @danafarber.bsky.social patient Necee Regis was recently featured on @wgbh.org’s screen overlooking the Mass Pike. Learn more about her story and art: bit.ly/4m53iR3

Since the Phyllis F. Cantor Center for Research in Nursing and Patient Care Services was established 25 years ago, @danafarber.bsky.social nurse scientists have published over 1,000 peer-reviewed studies while building a model integrating research into patient care. Read more at bit.ly/4bZyk8A

Today and every day, we thank the incredible doctors at @danafarber.bsky.social and beyond for making a difference in the lives of patients and their families. Their expert, compassionate, and equitable care brings us closer to a world free from the burden of cancer. 💙 #NationalDoctorsDay

8 Treatments for Bladder Cancer Pain: @danafarber.bsky.social’s Dr. Stephanie Berg discusses pain and symptom management with @everydayhealth.bsky.social: bit.ly/4ss0YGq

Exposure to clinical medicine and research from an early age led to @danafarber.bsky.social President and CEO Dr. Benjamin L. Ebert to a career focused on the genetic foundation and treatment of hematologic malignancies. Read more in @ascopost.bsky.social: bit.ly/4sRrqJT

Featured on 7News Boston: Dana-Farber President and CEO Benjamin L. Ebert says the new food pantry at @danafarber.bsky.social supported by Stop & Shop will help combat #foodinsecurity which he called a “major determinant of outcome” in patients facing cancer and their households. ➡️ bit.ly/4t9UtIa

Congrats to @danafarber.bsky.social’s Dr. Kathleen Burns on being named an @aaas.org Fellow for pioneering contributions to understanding the role of mobile genetic elements in cancer. ➡️ bit.ly/47pobAy

Innovations in Cancer Drug Research: Still time to register in-person or virtually to attend the 5th Transatlantic Exchange in Oncology at @danafarber.bsky.social on Friday, March 27 in collaboration with @gustaveroussy.fr. Keynote by Alice Shaw, MD, PhD. Read more here: bit.ly/4bwDLNf

Today @danafarber.bsky.social launched its new food pantry with a $1 million gift from Stop & Shop to help combat #foodinsecurity and advance health equity during cancer treatment. It currently serves pediatric households with plans to expand access. Read more: bit.ly/4symGZa

In a new study published in @natmed.nature.com, @danafarber.bsky.social researchers. led by @ireneghobrial.bsky.social, introduce PANGEA-SMM, a free tool that dynamically predicts progression in smoldering multiple myeloma. Read more: bit.ly/47j6cvw

Transatlantic Exchange in Oncology on Friday, March 27, at @danafarber.bsky.social in collaboration with @GRoussyEdu ➡️Epigenetic therapies ➡️Microbiome-driven immunity ➡️Cellular pathway reprogramming Register here: bit.ly/47P4emM

Featured on @wbztv.bsky.social this weekend, @danafarber.bsky.social’s @mattyurgelun.bsky.social discusses young-onset colorectal cancer and lynch syndrome. March is #ColorectalCancerAwareness month, and Sunday was #LynchSyndromeAwareness day. ➡️ bit.ly/4rRDjy6

Congrats to @narjustflorezmd.bsky.social on being recognized by @clrhenrysantana.bsky.social for her leadership and impact in our community at the @bostoncitycouncil.bsky.social Women’s History Month celebration. #WomensHistoryMonth

“Hope should not be restricted to just affluent communities. Hope should be accessible to all.” @danafarber.bsky.social’s Chief Clinical Access Officer, Dr. Chris Lathan, discusses the life expectancy gap between Black residents and other Bostonians in this @BostonGlobe article: bit.ly/4b9vyys

Thank you, Kim Carrigan and Mark Ockerbloom from @boston25news.com for inviting @danafarber.bsky.social's Dr. Kimmie Ng onto the Carrigan & Company Podcast to discuss signs, symptoms, and research of young-onset colorectal cancer. March is #ColorectalCancerAwareness month. 📺 bit.ly/3Pg4BjT

In a new study published in @natmethods.nature.com, @danafarber.bsky.social’s @nickpolizzi.bsky.social uses features from a pretrained neural network to train a logistic regression model, AF2BIND, which could be used for drug discovery and uncovering functional sites in proteins. ➡️ rdcu.be/e7SnX

Congratulations to Lily Kabarame, BSN, RN, recipient of the 2026 New England Regional Black Nurses Association Excellence in Nursing Practice Award. Lily is recognized for her work as an oncology nurse navigator with the @danafarber.bsky.social Lank Center for Genitourinary Oncology.

Why is #colorectalcancer rising in younger adults? Featured in @katiecouric.bsky.social Media, @danafarber.bsky.social’s Dr. Kimmie Ng discusses the top theories researchers are investigating and risk factors you don't want to ignore. #ColorectalCancerAwarenessMonth ➡️ bit.ly/4ujThU7

In a study published in @cp-cancercell.bsky.social, @danafarber.bsky.social researchers led by Dr. David Barbie uncovered why small cell lung cancer can stay largely out of reach of the immune system, even when the cancer cells themselves are vulnerable to immune attack. #SCLC bit.ly/4ucsJnp

“If the right type of cell is there, maybe we can bolster the immune response. In particular, that immunological aim of the GLP-1 study is exciting to me,” @danafarber.bsky.social’s Dr. Erica Pimenta tells Targeted Oncology about key findings from her liposarcoma research. ➡️ bit.ly/40bFGAs

New research in @natcomms.nature.com by @danafarber.bsky.social’s @mishabeltran.bsky.social and Varadha Balaji Venkadakrishnan, PhD, reveals how prostate cancer becomes resistant to treatment and DNA methylation and EZH2 activity drive neuroendocrine prostate cancer. ➡️ bit.ly/4sk61bg

New research published by @danafarber.bsky.social’s Judith Agudo, PhD, and colleagues in @nature.com today reveals a new strategy to prevent the metastasis of triple-negative breast cancer. ➡️ bit.ly/4rLuOFj

Cancer Grand Challenges has awarded $25 million to team ILLUMINE, a group of leading scientists around the world including @danafarber.bsky.social’s Dr. Cathy Wu, who will work to unlock the potential of the cancer dark proteome. bit.ly/4d1AxSV

"LITESPARK-022 is the first adjuvant trial in kidney cancer to show a benefit for a combination versus a PD-1 agent alone." @danafarber.bsky.social’s Toni Choueiri, MD, featured in Fierce Pharma discussing kidney cancer research he presented at #ASCOGU. ➡️ bit.ly/3MTz0nq

"The Cancer No One Can Explain" - Kicking off #ColorectalCancerAwareness month with this great piece in @nautil.us magazine featuring a Q&A about young-onset colorectal cancer with @danafarber.bsky.social’s Dr. Leah Biller. Read more here: bit.ly/4b4lRju

At #ASCOGU26: @danafarber.bsky.social’s Dr. Brad McGregor provides an update on the STRIKE! clinical trial which looks at short term intensified pembrolizumab and tivozanib for high-risk renal cell carcinoma.

Research at #ASCOGU: @danafarber.bsky.social’s Dr. Alicia Morgans provides insights from the ARANOTE trial during a poster session. The poster looks at the impact of hospitalizations on health-related quality of life and overall survival in metastatic castration-sensitive prostate cancer.

"The most frightening thing is, we don’t completely understand why these rates are rising in young people without risk factors” - @danafarber.bsky.social’s Dr. Kimmie Ng speaks with 7News Boston about the rising rate of young-onset colorectal cancer. ➡️ bit.ly/4sf4bZk